Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa trial of RH5.1/AS01 blood-stage malaria vaccine
2016-001718-31Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of RH5.1 and AS01B in Falciparum malaria (PF), sponsored by University of Oxford. Primary endpoint: Safety and reactogenicity. Started Jul 2016; status: completed.
02
Drugs
RH5.1AS01B
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on 2016-001718-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001718-31.